Horizon Pharma (HZNP): Raising PT On RPTP Deal - Mizuho

September 13, 2016 6:14 AM EDT
Get Alerts HZNP Hot Sheet
Price: $16.80 -0.36%

Rating Summary:
    13 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade HZNP Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on Horizon Pharma (NASDAQ: HZNP) and raised her price target to $33.00 on the RPTP deal. The analyst views the deal as a sensible, accretive, "building block" deal that should continue to diversify the business away from primary care. The analyst also expects HZNP to benefit from yet another round of 9.9% price increases in Aug, in anticipation of additional contracts.

The $33PT is up from $30 and remains based on a DCF with a 13% WACC and 3% terminal growth rate.

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $18.89 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Mergers and Acquisitions

Related Entities

Raising Prices, Irina Koffler

Add Your Comment